{"organizations": [], "uuid": "c759dc6f691771e683b3769f601dafa6ccfb92b5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180404.html", "section_title": "Archive News &amp; Video for Wednesday, 04 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-conatus-pharmaceuticals-announces/brief-conatus-pharmaceuticals-announces-top-line-results-from-phase-2b-polt-hcv-svr-clinical-trial-idUSASC09UY9", "country": "US", "domain_rank": 408, "title": "BRIEF-Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.292, "site_type": "news", "published": "2018-04-05T04:23:00.000+03:00", "replies_count": 0, "uuid": "c759dc6f691771e683b3769f601dafa6ccfb92b5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-conatus-pharmaceuticals-announces/brief-conatus-pharmaceuticals-announces-top-line-results-from-phase-2b-polt-hcv-svr-clinical-trial-idUSASC09UY9", "ord_in_thread": 0, "title": "BRIEF-Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "conatus pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "nash", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Conatus Pharmaceuticals Inc:\n* CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL\n* THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION\n* BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION\n* CONATUS PHARMACEUTICALS INC - ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019\n* CONATUS PHARMACEUTICALS INC - ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T04:23:00.000+03:00", "crawled": "2018-04-05T17:21:05.029+03:00", "highlightTitle": ""}